Series - Raising Capital

The Biotechnology Innovation Organization (BIO) and BioFlorida present "The Transformative Potential of Genomic Medicine 2.0." Genomic technologies create powerful tools that have the potential to diagnose, treat, and permanently subdue many human diseases. Technologies such as gene therapy, gene editing, and CRISPR are just some of the newest terms as researchers and clinicians work on new approaches to develop lifesaving, disease-altering treatments. This session provides in-depth discussion regarding how treatment is changing in rare diseases and the sickle cell community, and how public and private payers are approaching coverage of these crucial treatments. The session opens with statements from two legislators, then the panel features two patients and an expert in alternative payment models to provide information and answer questions from policymakers.  

Representative Sam Garrison
Florida House of Representatives
House Health and Human Services Committee Republican Majority Whip

Senator Bobby Powell
Florida State Senate
Legislative Black Caucus Chair

Nearly 30 life science SPAC deals have closed or announced definitive agreements within the past year, helping private companies access new capital and public markets quickly. However, even recent traditions in SPAC deal terms continue to evolve because of statements from regulators regarding the accounting for warrants, shifts in investor expectations, and the availability of PIPE deal supporters, among other factors. View this Biotechnology Innovation Organization (BIO) webinar's discussion of best practices for negotiating SPAC deal terms in today’s market to maximize raising capital to serve biomedical innovation. Learn from the following deal-making experts as they answer audience questions during the session.  

This session is part of the "Anatomy of a SPAC Deal" Webinar Series, sponsored by Chardan.

More than 60 public Special Purpose Acquisition Companies (SPACs) are currently seeking life science companies for merger deals. Join this Biotechnology Innovation Organization (BIO) webinar to learn which financial, scientific, and managerial characteristics are most appealing to SPAC sponsors and the critical factors biotech management teams should prioritize in reviewing SPACs as potential fundraising sources. Learn from the following deal-making experts as they answer the moderator's and the audience's questions during the session.  

This session is part of BIO's "Anatomy of a SPAC Deal" Webinar Series, sponsored by Chardan.

Calculating the Benefits of Biotechnology Climate change is a clear and present danger to society. Industries and governments are taking action to confront this crisis, committing to sustainability goals that reduce environmental impact and improve the health and well-being of communities. To be confident in sustainability claims, it is critical to accurately calculate the environmental benefits of biotechnologies and how that value transfers through complex supply chains. Our BIO Impact webinar will explore efforts to promote consistent sustainability accounting, as well as highlight BIO members’ transformative innovations and the partnerships & collaborations that are leveraging the demands of climate mitigation and propelling a resilient biobased economy of the future.

Join the Biotechnology Innovation Organization (BIO) for an expert discussion on Section 112, focusing on the enablement of functional language. We'll review how this is playing out in district court litigation and in the PTAB and also discuss potential prosecution strategies. The discussion will focus on recent enablement-related cases, including Amgen v. Sanofi and the cases that led to that landmark decision.